SHANGHAI – Zai Labs Ltd. has kicked off a phase III China study of ZL-2306 (niraparib), a poly ADP-ribose polymerase (PARP) inhibitor that prolongs the life of women with ovarian cancer. Read More
HONG KONG – Ever since the Hong Kong Stock Exchange (HKEX) lowered the listing bar for biotech startups that are yet to generate revenue, the bourse keeps receiving applications from biotech firms both inside and outside China. Read More
DUBLIN – Nextbiotix SA raised €7 million (US$8.2 million) in a series A round to take a microbiome-based therapy for treating inflammatory bowel disease (IBD) into clinical trials. Read More
A study by scientists at New Zealand's Otago University has opened the door to the discovery of new biomarkers that potentially predict whether melanoma patients will respond to treatment with novel checkpoint inhibitor immunotherapies. Read More
NEW DELHI, India – India's drugs standards regulatory authority has recommended the introduction of a track and trace system for the top 300 pharmaceutical brands sold by 66 companies, in a bid to curb the sale of counterfeit or substandard drugs in the country. Read More
Realm Therapeutics plc, of Malvern, Pa., confirmed the effectiveness of registration of its American depositary shares to trade on Nasdaq and instructed holders of the company's AIM-listed shares about how to convert those shares to ADSs if they wish. Read More
Neovii Pharmaceuticals AG, of Rapperswil, Switzerland, has granted Singapore-based Mundipharma Pte. Ltd. rights to develop and distribute its polyclonal antibody immunosuppressant, Grafalon (anti-human T-lymphocyte immunoglobulin), in China and Japan from the end of October. Read More
